154 completed, 37 unknown, 11 terminated, 10 withdrawn. 69 Phase 2, 65 Phase 3, 48 Phase 4, 12 Not applicable, 11 Phase 1.
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus. - Hepatitis C, RDT | Early Phase 1 | Recruiting | Médecins du Monde | 3040 | 2024-10-03 | 2026-10-09 |
| Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily - Heptatitis C | Not applicable | Completed | Indus Hospital and Health Network | 192 | 2024-01-10 | 2026-07-14 |
| Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia Sofosbuvir/Daclatasvir - HCV Infection | Not applicable | Active not recruiting | ANRS, Emerging Infectious Diseases | 21000 | 2023-08-07 | 2025-12-04 |
| Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan Epclusa (nucleotide HCV NS5B polymerase inhibitors). - Hepatitis C | Not applicable | Enrolling by invitation | Queen Mary University of London | 318 | 2023-06-01 | 2025-11-21 |
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Bevacizumab, Atezolizumab, Sofosbuvir - Liver Cancer | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-03-17 | 2024-12-31 |
| The Efficacy of Vosevi in Treating DAA-experienced Patients Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C, Medication Reaction | Recruiting | The Third Affiliated Hospital of Guangzhou Medical University | 200 | 2023-02-28 | 2024-03-13 | |
| Elimination of Hepatitis C Virus Among Users of Substances Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] - Hepatitis C in Substance Users | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 1000 | 2022-11-15 | 2022-09-29 | |
| Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera sofosbuvir and daclatasvir - Hepatitis C, Chronic | Early Phase 1 | Unknown | Assiut University | 40 | 2022-10-01 | 2022-07-26 |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets - HCV | Phase 3 | Unknown | Ain Shams University | 30 | 2022-06-05 | 2023-05-11 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead) - Hepatitis C | Phase 4 | Unknown | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 1800 | 2022-03-09 | 2023-11-13 |
| Hepatitis C Treatment Study in Myanmar Sofosbuvir 400 mg - Hepatitis C | Withdrawn | Myanmar Oxford Clinical Research Unit | 2022-01-01 | 2021-12-17 | ||
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet - Hepatitis C, Liver Inflammation | Not applicable | Terminated | Kirby Institute | 21 | 2021-02-12 | 2026-05-26 |
| Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) Sofosbuvir 400 MG plus Daclatasvir 200mg - COVID-19 | Phase 3 | Unknown | Mansoura University | 50 | 2020-12-28 | 2021-02-24 |
| COVID-19 Prophylaxis South Africa (COVER HCW) Nitazoxanide, Sofosbuvir/Daclatasvir - Covid19, SARS-CoV Infection | Phase 2 | Completed | University of Witwatersrand, South Africa | 1950 | 2020-12-08 | 2022-06-07 |
Showing 20 of 224. Sign in to see all of them.
Hepatitis C (135) · Hepatitis C, Chronic (57) · Fibrosis (13) · Hepatitis (13) · COVID-19 (7) · Liver Diseases (7) · Acquired Immunodeficiency Syndrome (6) · Hepatitis, Chronic (6) · Bronchiolitis Obliterans Syndrome (4) · Digestive System Diseases (4) · Hepatitis B (4) · Hepatitis, Viral, Human (4) · RNA Virus Infections (4) · Carcinoma, Hepatocellular (3) · Enterovirus Infections (3)
Gilead Sciences (45) · Bristol-Myers Squibb (11) · AbbVie (6) · Humanity and Health Research Centre (6) · Kirby Institute (6) · ANRS, Emerging Infectious Diseases (5) · Tehran University of Medical Sciences (5) · Ain Shams University (4) · Assiut University (4) · Genuine Research Center, Egypt (4) · Tanta University (4) · Egyptian Liver Hospital (3) · Kawin Technology Share-holding Co., Ltd. (3) · Massachusetts General Hospital (3) · Merck Sharp & Dohme LLC (3)
United States (77) · Egypt (31) · Australia (23) · Puerto Rico (22) · China (20) · New Zealand (19) · Canada (16) · Germany (14) · Spain (14) · France (13) · United Kingdom (12) · Italy (9) · India (8) · Netherlands (6) · Russia (6)
Robert H. Hyland, DPhil (5) · Ahmed Elshafeey, Ph.D. Pharma (4) · George Lau, MD (3) · Kathryn Kersey, MSc (3) · Lai Wei, M.D. (3) · Anuj Gaggar, MD, PhD (2) · Charles Chasela, PhD (2) · Eric Cohen, MD (2) · George KK Lau, MD (2) · Henry Masur, M.D. (2)
PMID 23607594, PMID 25040192, PMID 25583164, PMID 23607593, PMID 24209977, PMID 26575258, PMID 23281974, PMID 24428467, PMID 24795201, PMID 26261007, PMID 26596948, PMID 27847279, PMID 30853642, PMID 36740893, PMID 37671831, PMID 11413125, PMID 12450640, PMID 12618532, PMID 12823087, PMID 15147119, PMID 15158348, PMID 15560058, PMID 15637534, PMID 17593061, PMID 17635375, PMID 17695343, PMID 17850410, PMID 18266997, PMID 19053983, PMID 19330875, PMID 19897823, PMID 20951424, PMID 21371579, PMID 21441689, PMID 22706730, PMID 22762136, PMID 23059806, PMID 23172780, PMID 23300053, PMID 23499158, PMID 23499440, PMID 23807378, PMID 23982366, PMID 24010641, PMID 24067879, PMID 24155107, PMID 24262278, PMID 24316172, PMID 24720702, PMID 24983321
2014 (8), 2015 (6), 2017 (3), R01DA026727 (2), UM1AI068636 (2), 2016 (1), R01DA033777 (1), R01DA047952 (1), R34DA061732 (1), U01AI195193 (1), U54DK083909 (1), UL1TR001082 (1)